Answers are grounded in this paper and cite their sources.
T2D is a well-established risk factor for development and progression of CKD. KDIGO recommends categorization of risk by likelihood of progression to ESKD. Compared to placebo, empagliflozin decreases likelihood of worsening (OR 0.70, 95 % CI 0.62-0.78) and increases likelihood of improvement (OR 1.56, 95 % CI 1.30-1.86) in KDIGO risk category.
No takes yet. Share an insight, caveat, or question.
Weingold et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: